FDA Transparency Push Expands to Monitoring Safety of Vaccines and Other Regulated Products
Frank Vinluan / medcitynews - The FDA said consolidating safety reporting into a single platform, the Adverse Event Monitoring System (AEMS), will increase transparency and reduce costs. But like the legacy systems it replaces, AEMS reports are unverified so causation and frequency of…
AI Summary: The FDA is consolidating multiple safety reporting systems into a single public Adverse Event Monitoring System to centralize reports for drugs, biologics, vaccines, cosmetics and animal products. The move aims to improve transparency, reduce fragmented reporting, and streamline monitoring — a tidy solution if it works as promised.
Engineering CAR T cells to secrete VEGF-neutralizing scFvs enhances antitumor activity against solid tumors
Torahito A. Gao, Ryan M. Shih, Justin D. Clubb, Shao-Hsi Hung, Tanya Singh, Laura B. James-Allan, Ga / science - Science Translational Medicine, Volume 18, Issue 839, March 2026.
AI Summary: Researchers engineered CAR‑T cells to secrete VEGF‑neutralizing single‑chain antibodies, improving infiltration and antitumor activity against solid tumors in preclinical models. By locally neutralizing VEGF, the approach remodels the tumor microenvironment and enhances CAR‑T efficacy, offering a plausible strategy to overcome the long‑standing barrier of poor CAR‑T performance in solid cancers.
White House autism briefing linked to swift shifts in prescribing patterns
medicalxpress - A White House briefing in September 2025 that raised concerns about acetaminophen use during pregnancy and promoted the drug leucovorin as a potential autism treatment was followed by sharp changes in how doctors prescribed those medications nationwide, a…
AI Summary: A White House briefing warning about acetaminophen in pregnancy and promoting alternate therapies led to an immediate, measurable decline in ER acetaminophen orders for pregnant patients. The episode shows how high‑profile public messaging can swiftly reshape clinical behavior — for better or worse — and raises questions about evidence, communication and unintended consequences.
Eli Lilly's new program aims to boost employer coverage of GLP-1s
Shelby Livingston / endpoints - With insurance coverage of weight loss medications stalled, Eli Lilly has developed a program to give employers another way to pay for their workers' GLP-1 treatments. The pharma giant on Thursday announced the launch of ...
AI Summary: Eli Lilly unveiled an Employer Connect program designed to help employers expand coverage for GLP‑1–class weight‑loss drugs amid stalled insurer uptake. The initiative offers new contracting and access pathways for workplaces, addressing demand while prompting debate over whether it changes the underlying benefit‑design economics. It’s helpful—if you don’t expect a revolution.
ASCO GU 2026 Highlights: Belzutifan + Lenvatinib and Pembrolizumab in RCC – IUCS
oncodaily - International Urology Cancer Summit shared a post on LinkedIn: “IUCS Journal Club – Highlights from ASCO GU 2026: Targeting HIF-2α in RCC. This Journal Club session reviews the data from […]
AI Summary: At ASCO GU, investigators showcased belzutifan‑based combinations for renal cell carcinoma, including belzutifan with lenvatinib and perioperative belzutifan plus pembrolizumab. Data presented indicate these HIF‑2α‑targeted regimens can extend disease‑free intervals in high‑risk clear‑cell RCC, prompting interest in integrating hypoxia‑axis inhibitors into multimodal kidney‑cancer care.
New FDA bonus pilot to address 'workforce challenges'
Max Bayer / endpoints - A new bonus pilot program meant to reward fast-working FDA reviewers will be funded in part by money from industry user fees, the first details on how Commissioner Marty Makary plans to finance the incentive ...
AI Summary: The FDA has introduced a pilot program offering performance bonuses to expedite regulatory reviews, aiming to tackle reviewer workload and improve timeliness. Funded partly by industry user fees, the initiative seeks to reward faster, high‑quality reviews while balancing independence and efficiency—proof that carrots sometimes replace the endless stick of overtime.
FDA lifts hold on Intellia trial
Ella Jeffries / beckershospitalreview - The FDA has lifted a clinical hold on Intellia Therapeutics’ phase 3 Magnitude trial of nexiguran ziclumeran, or nex-z. The trial was paused Oct. 29 after a patient developed grade 4 liver transaminase elevations and elevated bilirubin following a Sept. 3…
AI Summary: The FDA has lifted clinical holds on Intellia Therapeutics’ Phase 3 gene‑editing trials, allowing the company to resume patient enrollment and advance its nexiguran (nex‑z) development program. Regulators appear satisfied with submitted safety updates, clearing a major regulatory hurdle and moving the gene-editing program back toward its clinical milestones.
Optum Rx, Caremark making ‘significant progress’ in settlement talks with FTC
Rebecca Pifer Parduhn / healthcaredive - It’s looking increasingly likely that the UnitedHealth and CVS drug middlemen will also make peace with federal regulators, after Cigna agreed to a sweeping settlement in the insulin lawsuit last month.
AI Summary: Federal regulators and two pharmacy benefit managers are reportedly making substantial progress toward resolving an FTC antitrust probe tied to insulin pricing and PBM practices. Negotiations aim to settle allegations without protracted litigation, potentially changing how PBMs operate and how insulin costs are managed for states and patients.
Moderna to Pay Up to $2.25B to Settle Patent Suit Over Covid-19 Vaccine Technology
Frank Vinluan / medcitynews - Under the settlement, Genevant Sciences and Arbutus Biopharma will grant Moderna a non-exclusive license to their lipid nanoparticle technology for mRNA delivery in infectious disease vaccines. If Moderna’s full financial payout to the companies is reache…
AI Summary: Moderna has agreed to settle long-running patent disputes over its COVID-19 vaccine technology for up to $2.25 billion, resolving litigation with several claimants. The deal provides Moderna with broad licensing rights and clears a major legal uncertainty, allowing the company to move forward without another courtroom cliffhanger.
Servier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma
Frank Vinluan / medcitynews - Day One Biopharmaceuticals is Servier’s biggest acquisition yet, topping the $2.4 billion it paid to buy Shire’s cancer business in 2018. Day One markets Ojemda, approved for treating pediatric low-grade glioma, the most common type of brain cancer in chi…
AI Summary: Servier is buying Day One Biopharmaceuticals for about $2.5 billion to bolster its rare oncology portfolio, gaining access to promising targeted therapies. The deal expands Servier’s presence in specialty cancer medicines and aligns with its strategic push into rare tumors, with integration and regulatory steps expected to follow.
Hospitals urge regulators to halt drugmakers’ expanded 340B data policies
Emily Olsen / healthcaredive - The American Hospital Association argues new policies from Eli Lilly and Novo Nordisk requiring providers to submit more claims data on dispensed 340B drugs is onerous and unlawful.
AI Summary: Hospitals and provider groups are urging federal regulators to halt new drugmaker policies that expand claims-data reporting tied to 340B discounts, calling the requirements unlawful and administratively burdensome. The dispute pits safety-net providers against manufacturers seeking program transparency — a classic tug-of-war with patients’ financial stakes caught in the middle.
GLP‑1 drugs may fight addiction across every major substance, according to a study of 600,000 people
medicalxpress - A patient of mine, a veteran who had tried to quit smoking for over a decade, told me that after he started a GLP-1 drug for his diabetes, he lost interest in cigarettes. He didn't use a patch. He didn't set a quit date. He simply lost interest. It happen…
AI Summary: A large observational analysis suggests GLP‑1 receptor agonists — the headline-grabbing diabetes and weight-loss drugs — are linked to reduced risk of developing and dying from substance use disorders across multiple substances. Researchers urge cautious optimism: signals are intriguing, but causality remains unproven and more controlled trials are needed before rewriting addiction treatment playbooks.
Groundbreaking new drug shows promise for treating children with a devastating form of epilepsy
livescience - An experimental treatment reduces seizures and other symptoms in children with a type of epilepsy called Dravet syndrome.
AI Summary: An experimental treatment markedly cut seizures and eased symptoms in children with Dravet syndrome, offering families dramatic improvements where few options existed. Early clinical data show promising safety and efficacy signals, but researchers caution larger, longer trials and regulatory review are needed before this becomes a routine option.
Adding Hormone Therapy to PORT Might Not Benefit Patients with Recurrent Prostate Cancer and PSA of 0.5 ng/mL or Less
esmo - Findings from the POSEIDON meta-analysis of the MARCAP consortium
AI Summary: A pooled POSEIDON meta-analysis from the MARCAP consortium found that adding androgen-deprivation therapy to post‑operative radiotherapy for recurrent prostate cancer with PSA ≤0.5 ng/mL does not improve outcomes meaningfully. In short: the extra hormonal punch may not be worth the side effects many patients will endure.
Novo Nordisk inks $2.1B oral obesity drug deal
Ella Jeffries / beckershospitalreview - Novo Nordisk has partnered with Vivtex Corp. to develop next-generation oral biologic medicines for obesity, diabetes and related conditions. Under the agreement, Vivtex will license its proprietary oral drug-delivery technologies to Novo Nordisk and is e…
AI Summary: Novo Nordisk has struck a multibillion‑dollar deal with Vivtex to develop next‑generation oral biologic therapies for obesity and related metabolic diseases. The partnership funnels major R&D resources into oral delivery technology, signaling the company’s bet that pills — not injections — will be the next commercial battleground in weight‑loss medicine.
Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours
esmo - Findings from the PYNNACLE study
AI Summary: Clinical results from the PYNNACLE program demonstrate that rezatapopt, an oral small‑molecule p53 reactivator, produces antitumor activity in cancers driven by the TP53 Y220C mutation. Early data validate targeting a previously “undruggable” p53 variant, offering a concrete therapeutic strategy and sparking excitement — and a few warranted caveats — about broader applicability.
Novartis closes Avidity deal as rare heart disease spinout launches
Lei Lei Wu / endpoints - Atrium Therapeutics launched Friday morning as Novartis closed the $12 billion deal to buy Avidity Biosciences and its RNA muscle therapies. The spinout will take on Avidity’s early-stage programs for genetic cardiomyopathies — heart muscle diseases ...
AI Summary: Novartis completed its Avidity Biosciences transaction and backed the launch of Atrium Therapeutics, a newly funded spinout focused on RNA therapies for rare cardiac conditions. Atrium inherits delivery platforms and early programs with substantial capital, as Novartis reshuffles assets to accelerate its RNA strategy — because apparently doubling down on hot modalities never gets old.
Merck Splits Oncology Business Unit as Keytruda Patent Expiry Nears
oncodaily - On February 23, 2026, Merck announced a reorganization of its Human Health structure into two business units: an Oncology Business Unit and a Specialty, Pharma & Infectious Diseases Business Unit. […]
AI Summary: Merck reorganized its Human Health structure to form a separate oncology business unit, positioning the company to defend and optimize its cancer franchise ahead of Keytruda patent pressures and to sharpen focus across therapeutic areas as part of a broader commercial realignment.
Boehringer wins accelerated approval for first-line use of lung cancer drug
Lei Lei Wu / endpoints - The FDA greenlit an expanded label for Boehringer Ingelheim’s lung cancer drug Hernexeos, marking the first use of the Commissioner's National Priority Voucher for a new indication. Boehringer won an accelerated
AI Summary: Regulators accelerated approval of Boehringer Ingelheim’s lung cancer therapy for first‑line use, leveraging a priority review mechanism that sped the timeline. The label expansion places the drug into earlier treatment settings, reflecting promising data and the efficiency (and occasional controversy) of voucher‑assisted regulatory pathways.
Novartis to build $23B radioligand therapy site
Ella Jeffries / beckershospitalreview - Novartis will construct a 46,000-square-foot radioligand therapy manufacturing site in Denton, Texas, as part of its $23 billion U.S. investment. The facility will be Novartis’ fifth radioligand therapy site in the U.S. and its first in Texas, according t…
AI Summary: Novartis announced plans to construct a 46,000‑square‑foot radioligand therapy manufacturing facility in Denton, Texas, part of a broader $23 billion U.S. expansion. The site aims to boost domestic production capacity for targeted radiopharmaceuticals, signaling Big Pharma’s bet that radioligand therapies will be a growth engine — and a lovely way to justify large real estate footprints.